clinical trial · NCT07216105
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Non-Small Cell Lung CancerColorectal CancerBreast CancerOvarian CancerEndometrial CarcinomaHead and Neck Squamous Cell CarcinomaFT836PaclitaxelCetuximabTrastuzumab
brief summary
This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.
started
Nov 4, 2025
primary completion
Jan 1, 2028
completion
Jan 1, 2030
last updated
Apr 7, 2026
official title
A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol